385 related articles for article (PubMed ID: 25398821)
21. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
22. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
23. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
[TBL] [Abstract][Full Text] [Related]
24. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
25. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A
Adv Ther; 2016 May; 33(5):747-59. PubMed ID: 27085323
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Catalano M; Roviello G; Conca R; D'Angelo A; Palmieri VE; Panella B; Petrioli R; Ianza A; Nobili S; Mini E; Ramello M
Curr Cancer Drug Targets; 2020; 20(11):887-895. PubMed ID: 32957885
[TBL] [Abstract][Full Text] [Related]
27. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Nebot-Villacampa MJ; Zafra-Morales R; Alfaro-Olea A; Marín-Gorricho R; Casajús-Navasal A; Uriarte-Pinto M
J Oncol Pharm Pract; 2020 Apr; 26(3):603-611. PubMed ID: 31315550
[TBL] [Abstract][Full Text] [Related]
29. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.
Kokkali S; Tripodaki ES; Drizou M; Stefanou D; Magou E; Zylis D; Kapiris M; Nasi D; Georganta C; Ardavanis A
In Vivo; 2018; 32(3):653-657. PubMed ID: 29695574
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Tabernero J; Chiorean EG; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD
Oncologist; 2015 Feb; 20(2):143-50. PubMed ID: 25582141
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
[TBL] [Abstract][Full Text] [Related]
32. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
[TBL] [Abstract][Full Text] [Related]
33. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
35. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Hu ZI; Bendell JC; Bullock A; LoConte NK; Hatoum H; Ritch P; Hool H; Leach JW; Sanchez J; Sohal DPS; Strickler J; Patel R; Wang-Gillam A; Firdaus I; Yu KH; Kapoun AM; Holmgren E; Zhou L; Dupont J; Picozzi V; Sahai V; O'Reilly EM
Cancer Med; 2019 Sep; 8(11):5148-5157. PubMed ID: 31347292
[TBL] [Abstract][Full Text] [Related]
37. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
40. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
